936024-96-3

Basic information

• Product Name: CarbaMic acid, N-[(1S)-1-[3,4-dihydro-5-Methyl-3-(2-Methylphenyl)-4-oxo-2-quinazolinyl]ethyl]-, 1,1-diMethylethyl ester
• Synonyms: CarbaMic acid, N-[(1S)-1-[3,4-dihydro-5-Methyl-3-(2-Methylphenyl)-4-oxo-2-quinazolinyl]ethyl]-, 1,1-diMethylethyl ester;(S)-tert-butyl (1-(5-methyl-4-oxo-3-(o-tolyl)-3,4-dihydroquinazolin-2-yl)ethyl)carbamate
• CAS NO: 936024-96-3
• Molecular Formula: C23H27N3O3
• Molecular Weight: 393.47878
• Mol File: 936024-96-3.mol

Chemical Properties

• Melting Point: 130-137 °C
• Appearance: /
• Density: 1.16±0.1 g/cm3(Predicted)
• PKA: 11.51±0.46(Predicted)
• CAS DataBase Reference: CarbaMic acid, N-[(1S)-1-[3,4-dihydro-5-Methyl-3-(2-Methylphenyl)-4-oxo-2-quinazolinyl]ethyl]-, 1,1-diMethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: CarbaMic acid, N-[(1S)-1-[3,4-dihydro-5-Methyl-3-(2-Methylphenyl)-4-oxo-2-quinazolinyl]ethyl]-, 1,1-diMethylethyl ester(936024-96-3)
• EPA Substance Registry System: CarbaMic acid, N-[(1S)-1-[3,4-dihydro-5-Methyl-3-(2-Methylphenyl)-4-oxo-2-quinazolinyl]ethyl]-, 1,1-diMethylethyl ester(936024-96-3)

Safety Data

• Hazardous Substances Data: 936024-96-3(Hazardous Substances Data)

Upstream product

• 936024-94-1 tert-butyl (S)-1-(5-methyl-4-(o-tolylimino)-4H-benzo[d][1,3]oxazin-2-yl)ethylcarbamate 
• 936025-18-2 tert-butyl (S)-(1-(2-methyl-6-nitro-N-(o-tolyl)benzamido)-1-oxopropan-2-yl)carbamate 
• 371244-06-3 2-amino-6-methyl-N-o-tolylbenzamide 
• 15761-38-3 L-N-Boc-Ala 
• 66232-57-3 2-methyl-6-nitrobenzoyl chloride 
• 95-53-4 o-toluidine 
• 4389-50-8 2-amino-6-methylbenzoic acid 
• 13506-76-8 2-methyl-6-nitrobenzoic acid 
• 936024-93-0 tert-butyl (S)-1-[3-methyl-2-(o-tolylcarbamoyl)phenylamino]-1-oxopropan-2-ylcarbamate 
• 936024-98-5 2-methyl-6-nitro-N-(o-tolyl)benzamide 

Relevant articles and documents

COMPOUNDS, COMPOSITIONALS, AND METHODS FOR TREATING T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA

In an aspect, the disclosure provides for compounds (II), compositions, and methods of administering the compounds and compositions to a patient in need thereof. In another aspect, the disclosure relates to compounds and compositions for treating cancer,

A novel highly stereoselective synthesis of 2,3-disubstituted 3H-quinazoline-4-one derivatives

Figure presented An efficient three-step synthesis of chiral 3H-quinazoline-4-one derivatives from commercial materials is disclosed. The Mumm reaction of imidoyl chloride with α-amino acids followed by reductive cyclization affords enantiomerically pure (ee >93%) quinazoline-4-ones in good overall yield. A comparison with existing approaches indicates that this method is superior for hindered substrates.